China SXT Pharmaceuticals (SXTC) Competitors $2.32 -0.02 (-0.81%) As of 12:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SXTC vs. ENVB, RDHL, SNPX, REVB, MTNB, CNSP, QLGN, AWH, THAR, and ENSCShould you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include Enveric Biosciences (ENVB), RedHill Biopharma (RDHL), Synaptogenix (SNPX), Revelation Biosciences (REVB), Matinas Biopharma (MTNB), CNS Pharmaceuticals (CNSP), Qualigen Therapeutics (QLGN), Aspira Women's Health (AWH), Tharimmune (THAR), and Ensysce Biosciences (ENSC). These companies are all part of the "pharmaceutical products" industry. China SXT Pharmaceuticals vs. Enveric Biosciences RedHill Biopharma Synaptogenix Revelation Biosciences Matinas Biopharma CNS Pharmaceuticals Qualigen Therapeutics Aspira Women's Health Tharimmune Ensysce Biosciences China SXT Pharmaceuticals (NASDAQ:SXTC) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking. Does the media favor SXTC or ENVB? In the previous week, China SXT Pharmaceuticals and China SXT Pharmaceuticals both had 1 articles in the media. Enveric Biosciences' average media sentiment score of 1.87 beat China SXT Pharmaceuticals' score of 0.94 indicating that Enveric Biosciences is being referred to more favorably in the news media. Company Overall Sentiment China SXT Pharmaceuticals Positive Enveric Biosciences Very Positive Which has better earnings & valuation, SXTC or ENVB? China SXT Pharmaceuticals has higher revenue and earnings than Enveric Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.82M0.93-$3.10MN/AN/AEnveric BiosciencesN/AN/A-$17.29M-$38.38-0.03 Does the MarketBeat Community believe in SXTC or ENVB? China SXT Pharmaceuticals received 76 more outperform votes than Enveric Biosciences when rated by MarketBeat users. Likewise, 61.65% of users gave China SXT Pharmaceuticals an outperform vote while only 60.00% of users gave Enveric Biosciences an outperform vote. CompanyUnderperformOutperformChina SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% Enveric BiosciencesOutperform Votes660.00% Underperform Votes440.00% Is SXTC or ENVB more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat Enveric Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Enveric Biosciences N/A -221.54%-164.32% Do analysts rate SXTC or ENVB? Enveric Biosciences has a consensus price target of $10.00, indicating a potential upside of 657.58%. Given Enveric Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Enveric Biosciences is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enveric Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, SXTC or ENVB? China SXT Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Do institutionals and insiders hold more shares of SXTC or ENVB? 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 3.2% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryChina SXT Pharmaceuticals beats Enveric Biosciences on 8 of the 13 factors compared between the two stocks. Get China SXT Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTC vs. The Competition Export to ExcelMetricChina SXT PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.69M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.4818.48Price / Sales0.93242.70394.56103.59Price / CashN/A65.8538.1834.62Price / Book0.086.516.774.25Net Income-$3.10M$143.21M$3.22B$248.23M7 Day Performance48.10%1.98%1.48%0.89%1 Month Performance-8.95%6.89%3.99%3.53%1 Year Performance-71.32%-2.52%16.15%5.08% China SXT Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTCChina SXT Pharmaceuticals0.9541 of 5 stars$2.32-0.8%N/A-72.4%$1.68M$1.82M0.0090ENVBEnveric Biosciences2.6584 of 5 stars$1.19+1.7%$10.00+740.3%-90.6%$2.94MN/A-0.0320Positive NewsRDHLRedHill Biopharma1.0685 of 5 stars$2.17-4.0%N/A-99.2%$2.89M$8.04M0.00210Analyst ForecastGap DownSNPXSynaptogenix2.7766 of 5 stars$2.05-3.3%$14.00+582.9%-48.7%$2.85MN/A-0.194Positive NewsGap DownREVBRevelation Biosciences0.4585 of 5 stars$3.14+1.9%N/A-91.0%$2.84MN/A-0.0110Short Interest ↑Negative NewsGap UpMTNBMatinas BiopharmaN/A$0.56-7.2%N/A+218.3%$2.83M$1.10M-0.1130CNSPCNS Pharmaceuticals1.817 of 5 stars$0.90+9.6%$25.00+2,681.2%-99.8%$2.65MN/A-0.015Gap UpQLGNQualigen TherapeuticsN/A$3.53+9.0%N/A-76.1%$2.60M$4.98M0.0050Short Interest ↓Negative NewsAWHAspira Women's Health2.0439 of 5 stars$0.08-12.5%$5.50+6,607.3%-97.5%$2.44M$9.18M-0.07110Positive NewsHigh Trading VolumeTHARTharimmune2.3205 of 5 stars$1.15+1.8%$17.00+1,378.3%-68.2%$2.43MN/A-0.122Upcoming EarningsNews CoverageENSCEnsysce Biosciences0.1784 of 5 stars$1.66-5.7%N/A-66.0%$2.33M$2.23M-0.0610 Related Companies and Tools Related Companies Enveric Biosciences Alternatives RedHill Biopharma Alternatives Synaptogenix Alternatives Revelation Biosciences Alternatives Matinas Biopharma Alternatives CNS Pharmaceuticals Alternatives Qualigen Therapeutics Alternatives Aspira Women's Health Alternatives Tharimmune Alternatives Ensysce Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SXTC Stock Free SXTC Stock Alerts